Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Pet3.2

Petrelintide – Forschung

Überwiegend Mechanismus / Beobachtung

5 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Petrelintide sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus mittelwertigen randomisierten Studien, veröffentlicht 2021–2026 mit einer typischen Studiengröße von 706 Teilnehmenden.

Basierend auf 5 Studien · 2 RCTs · 706 Teilnehmende insgesamt

Konfidenz

Geringe Konfidenz

Nach Outcome

Weight loss & obesityIn einer Phase-1-Studie mit multiplen aufsteigenden Dosen reduzierte Petrelintid das Körpergewicht nach 16 Wochen um bis zu ~8,6 % bei Erwachsenen mit Übergewicht/Adipositas, bei guter Verträglichkeit · Über ~16 Wochen
Überwiegend Mechanismus / Beobachtung4 Studien
Glucose & metabolic
Überwiegend Mechanismus / Beobachtung4 Studien
Safety profile
Zu wenige bewertete Studien2 Studien

Aktives Forschungsgebiet

5 Studien in den letzten 5 Jahren

20212026

1RCT2026

Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D · Diabetes Obes Metab (2026)

Quelle ansehen

2RCTn=706 · large study2021

Einfach gesagt: Mean percentage weight reductions from baseline were greater with all doses of cagrilintide (0·3-4·5 mg, 6·0%-10·8%) versus placebo (3·0%)... Weight reductions were also greater with cagrilintide 4·5 mg versus liraglutide 3·0 mg (10·8% vs 9·0%).

Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. · Lancet (2021)

Amylin-class context, NOT petrelintide. This is the phase-2 trial of cagrilintide — the OTHER long-acting amylin analogue (sibling compound) — included as the best human-RCT evidence for what the amylin-analogue class can achieve
706 adults with overweight/obesity on once-weekly subcutaneous cagrilintide 0.3-4.5 mg vs liraglutide vs placebo over 26 weeks: ~6.0-10.8% mean weight loss vs 3.0% placebo, top dose modestly beating liraglutide 3 mg
GI events (nausea, constipation, diarrhoea) and injection-site reactions were the most frequent adverse events — the class-typical safety pattern petrelintide also shows

Quelle ansehen

3Übersicht2026

Einfach gesagt: Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234.

Bailey CJ, Flatt PR, Conlon JM. · Peptides (2026)

Amylin-class context, NOT petrelintide-specific outcome data. Review of long-acting amylin-related peptides for obesity and type 2 diabetes, covering pramlintide, cagrilintide/CagriSema, amycretin, and petrelintide
Names petrelintide among recently developed long-acting amylin analogues 'shown strong efficacy as monotherapy in clinical trials' — but the detailed evidence summarised is for the broader class
Describes the established amylin mechanism: central satiety induction, slowed gastric emptying, suppressed prandial glucagon; GI side effects (especially nausea) common during initiation and up-titration but mostly resolving

Quelle ansehen

4Übersicht2026

Einfach gesagt: The article is a review of the emerging preclinical and clinical data regarding the application of peptide-based amylin receptor agonists... including pramlintide and cagrilintide... and investigational drugs, including ZP8396 and amycretin.

Rejili M, Hussain MS, Khan Y, Haouala F, Ganesan S, Sahoo S, Pal A, Arora V. · Vascul Pharmacol (2026)

Amylin-class context, NOT petrelintide-specific outcome data. Review of amylin-receptor agonists for obesity, including pramlintide, cagrilintide, KBP-series DACRAs, and investigational agents including ZP8396 (petrelintide) and amycretin
Details amylin-receptor (calcitonin-receptor + RAMP) molecular biology and central homeostatic/hedonic feeding control — the mechanistic foundation for the class
Frames ZP8396/petrelintide as an investigational agent within an emerging class with enhanced pharmacokinetics and GLP-1 synergy potential

Quelle ansehen

5Präklinisch2025

Einfach gesagt: Herein, we report the development of petrelintide, a potent, stable, long-acting analogue of human amylin that can be formulated at about neutral pH... Petrelintide is in clinical development as a potential treatment for weight management.

Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, Deryabina M, Demmer O, Skarbaliene J, Hamprecht DW, Rist W, Baader-Pagler T, Grube A, Heim-Riether A, Giehm L. · J Med Chem (2025)

Petrelintide-specific. Medicinal-chemistry discovery/development paper (Zealand Pharma with Boehringer Ingelheim) describing the design of petrelintide to overcome amylin's amyloid aggregation and short half-life
Engineered for chemical stability while retaining in vitro and in vivo potency, and formulable at near-neutral pH to enable potential co-formulation with other weight-management peptides
Establishes petrelintide as a stable long-acting human amylin analogue selected for clinical development in obesity

Quelle ansehen

In der Forschungsbibliothek ansehen

Petrelintide – Forschung

Überwiegend Mechanismus / Beobachtung

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.

Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.